Specialized Medical Mycology Center, Postgraduate Program in Medical Microbiology, Department of Pathology and Legal Medicine, Federal University of Ceará. Rua Cel. Nunes de Melo, 1315 - Rodolfo Teófilo - CEP: 60430-275, Fortaleza, Ceará, Brazil.
Postgraduate Program in Veterinary Sciences, College of Veterinary, State University of Ceará. Av. Dr. Silas Munguba, 1700, Campus do Itaperi, CEP: 60714-903, Fortaleza, Ceará, Brazil.
Med Mycol. 2020 Oct 1;58(7):906-912. doi: 10.1093/mmy/myz140.
Cryptococcus neoformans/Cryptococcus gattii are fungal pathogens that affect the central nervous system, mainly in immunocompromised individuals. Due to the limited pharmacological arsenal available for the treatment of cryptococcosis associated with cases of antifungal resistance of Cryptococcus spp. reported in some studies, the search for new compounds with antifungal potential becomes relevant. Thus, the objective of this study was to evaluate the inhibitory effect of phenothiazines (promethazine and chlorpromazine) on C. neoformans/C. gattii planktonic cells and biofilms. In vitro planktonic susceptibility testing was performed using the broth microdilution assay. The effect of phenothiazines was evaluated against biofilm formation and mature Cryptococcus biofilms. Biofilm morphology and ultrastructure were also evaluated by scanning electron microscopy. Promethazine and chlorpromazine showed antifungal activity against planktonic cells, with minimum inhibitory concentrations of 8-32 μg/ml and 4-16 μg/ml, respectively. As for biofilm formation, phenothiazines reduced biomass by 60% and metabolic activity by 90% at 64 μg/ml; while in mature biofilms, reductions of 85% and 90% in biomass and metabolic activity, respectively, were observed at 1024 μg/ml. Promethazine and chlorpromazine were also able to disrupt and fragment biofilms. In conclusion, promethazine and chlorpromazine have antifungal activity against planktonic cells and biofilms of Cryptococcus spp. These data show the potential of promethazine and chlorpromazine as antibiofilm drugs.
新型隐球菌/格特隐球菌是一种真菌病原体,主要影响免疫功能低下的个体的中枢神经系统。由于一些研究中报道了新型隐球菌属的抗真菌耐药相关病例,现有的抗真菌药物有限,因此寻找具有抗真菌潜力的新化合物变得尤为重要。本研究旨在评估吩噻嗪类药物(奋乃静和氯丙嗪)对新型隐球菌/格特隐球菌浮游细胞和生物膜的抑制作用。采用肉汤微量稀释法进行体外浮游药敏试验。评估了吩噻嗪类药物对生物膜形成和成熟隐球菌生物膜的影响。还通过扫描电子显微镜评估了生物膜形态和超微结构。奋乃静和氯丙嗪对浮游细胞均具有抗真菌活性,最小抑菌浓度分别为 8-32μg/ml 和 4-16μg/ml。对于生物膜形成,吩噻嗪类药物在 64μg/ml 时可将生物量减少 60%,代谢活性减少 90%;而在成熟生物膜中,生物量和代谢活性分别减少 85%和 90%,所需浓度为 1024μg/ml。奋乃静和氯丙嗪还能够破坏和使生物膜片段化。综上所述,奋乃静和氯丙嗪对新型隐球菌属的浮游细胞和生物膜具有抗真菌活性。这些数据表明奋乃静和氯丙嗪具有作为抗生物膜药物的潜力。